StockNews.com Begins Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX)

Equities researchers at StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research note issued to investors on Wednesday. The firm set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Stock Up 5.4 %

Shares of BTX stock opened at $0.29 on Wednesday. The company’s 50 day moving average is $0.59 and its 200 day moving average is $1.24. The firm has a market cap of $17.29 million, a price-to-earnings ratio of -0.13 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a 52-week low of $0.17 and a 52-week high of $10.10.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.